Evidence map›Paper›PMID 41024170›Full record

ArticleActa neuropathologica communications2025

Rab7a is required to degrade select blood-brain barrier junctional proteins after ischemic stroke.

Azzurra Cottarelli, Danny Jamoul, Mary Claire Tuohy, Sanjid Shahriar, Michael Glendinning, Grace Prochilo, Aimee L Edinger, Ahmet Arac, Dritan Agalliu

Abstract read
In one paragraph

Article in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Post-Translational Modifications in Traumatic Brain Injury: Decoding the Proteomic Landscape and Molecular Mechanisms of Secondary Injury.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Azzurra Cottarelli *Department of Neurology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
Danny Jamoul *Department of Neurology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
Mary Claire TuohyDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
Sanjid ShahriarDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
Michael GlendinningDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
Grace ProchiloDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
Aimee L EdingerDepartments of Developmental and Cell Biology and Pharmaceutical Sciences, University of California, Irvine, CA, 92697, USA.
Ahmet Arac *Department of Neurology, David Geffen School of Medicine, University of California in Los Angeles, Los Angeles, CA, 90095, USA.
Dritan Agalliu *Department of Neurology, Columbia University Irving Medical Center, New York, NY, 10032, USA. da191@cumc.columbia.edu.

Funding

Neuronal Regulation of Vascular Development and Maturation in the RetinaR01EY033994 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Dritan Agalliu · 2022 to 2026
$2.3M
Assessing the effects of peripheral immune activation on the NVU following TBI using a vascularized and perfused human blood/BBB modelR33HL159949 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI AGALLIU, DRITAN, LIS, RAPHAEL · 2023 to 2025
$2.2M
Assessing the effects of peripheral immune activation on the NVU following TBI using avascularized and perfused human blood/BBB model.R61HL159949 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI AGALLIU, DRITAN, LIS, RAPHAEL · 2021 to 2022
$1.9M
Developing a microfluidic human neurovascular unit system to investigate genetic and age-related risk factors in Alzheimer's diseaseRF1AG078352 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI AGALLIU, DRITAN, SPROUL, ANDREW ALEXANDER · 2022 to 2024
$1.4M
Developing a microfluidic human neurovascular unit system to investigate genetic and age-related risk factors in Alzheimer's diseaseR01AG078352 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Dritan Agalliu, Andrew Alexander Sproul · 2025 to 2026
$837k
Regulation of nutrient access by growth factors and mTORK08CA100526 · NCI · UNIVERSITY OF PENNSYLVANIA · PI EDINGER, AIMEE L · 2003 to 2007
$689k
Elucidating the role of RXRA in the myeloid lineage in post-infectious basal ganglia encephalitisR21NS130265 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI AGALLIU, DRITAN · 2022 to 2022
$442k
The role of autophagy in the neurovascular unit for the physiological response to stress.R21NS118891 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI AGALLIU, DRITAN, YAMAMOTO, AI · 2020 to 2020
$438k
Fondation Leducq FDNLEDQ 15CVD 02NCI NIH HHS K08 CA100526NEI NIH HHS R01 EY033994NEI NIH HHS R01EY033994NHLBI NIH HHS R33 HL159949NHLBI NIH HHS R61 HL159949NIA NIH HHS R01 AG078352NIA NIH HHS RF1 AG078352NIA NIH HHS RF1AG078352NINDS NIH HHS R21 NS118891NINDS NIH HHS R21 NS130265NINDS NIH HHS R21NS130265
6 · The paper itself

Abstract

The integrity of adherens and tight junctions is critical for blood-brain barrier (BBB) function in the healthy brain. Disassembly of cell junctions due to degradation of adherens and tight junction-associated proteins leads to acute BBB dysfunction after ischemic stroke, but the mechanisms of this process are not fully understood. Using genetic studies in mice coupled with histopathological analysis of the brains after ischemic stroke, we demonstrate that endothelial cell deletion of Rab7a, a small GTPase crucial for protein degradation through the endolysosomal system, reduces acute BBB leakage and improves neuronal health in mice after ischemic stroke by reducing the degradation of select adherens and tight junction proteins, and preserving the structural morphology of tight junctions at both confocal and electron microscopy level. Two pro-inflammatory cytokines, TNFα and IL1β, that are known to trigger disruption of paracellular barrier properties in primary brain endothelial cells in vitro and are upregulated after ischemic stroke, contribute to Rab7a activation in primary mouse brain endothelial cells (BECs). In contrast, oxygen-glucose deprivation does not activate Rab7a in mouse BECs. Rab7a is, therefore, critical for degradation of select BEC junctional proteins during the acute increase in BBB permeability after ischemic stroke.

Indexed as

Blood-Brain BarrierIschemic Strokerab GTP-Binding ProteinsTight Junction ProteinsAdherens JunctionsAnimalsEndothelial CellsMaleMiceMice, Inbred C57BLMice, Knockoutrab7 GTP-Binding ProteinsTight Junctionsrab7 GTP-Binding Proteinsrab7 GTP-binding proteins, mouserab GTP-Binding ProteinsTight Junction ProteinsAdherens junctionsBlood-brain barrierClaudin-5CytokinesInflammationIschemic strokeRab7aTight junctionsVE-CadherinZO-1

Identifiers

PMID41024170
PMCPMC12482340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.